Nasivin (Oxymetazoline Hydrochloride)

Oxymetazoline hydrochloride is a selective alpha‑1 and alpha‑2 adrenergic agonist. By activating these receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and opens the airway, providing rapid decongestion.

The appropriate dose of Nasivin is determined by a qualified healthcare professional based on the patient’s age, condition, and response. Typically, a few sprays into each nostril are used, but the exact regimen should follow the prescriber’s instructions.

Safety data for oxymetazoline hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Nasivin to weigh potential benefits against risks.

To request Nasivin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nasivin’s active ingredient, oxymetazoline, provides rapid, short‑term relief and is longer‑acting than some alternatives such as phenylephrine. However, like all topical decongestants, it should not be used for more than three consecutive days to avoid rebound congestion, a limitation shared across the class.

Nasivin should be stored at room temperature, preferably below 25 °C. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and store it in its original packaging until use.

Nasivin is administered as a nasal spray. The user gently inserts the tip into a nostril, depresses the pump to deliver the recommended number of sprays, and repeats in the other nostril if directed. The spray should be used only as prescribed and not exceed the recommended frequency.

Serious risks, though rare, include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, significant increases in blood pressure, cardiac arrhythmias, severe nasal ulceration, and allergic reactions such as rash or anaphylaxis. Any of these symptoms warrant immediate medical attention.

Nasivin should be avoided by individuals with known hypersensitivity to oxymetazoline or any formulation component, children under six years of age unless advised by a physician, patients with severe hypertension, coronary artery disease, or those taking monoamine oxidase inhibitors or other potent vasoconstrictors.